ClinicalTrials.gg
CompletedNCT05059977Updated Jan 12, 2024Results posted

A Study of TAK-881 in Healthy Adults

A Phase 1 interventional study of TAK-881 in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-12.

Sponsored by Takeda · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
19 Years to 50 Years
Sex
All
01

Study summary

The main aims of this study are to check for side effects from TAK-881 in healthy adults and to learn how much TAK-881 they can receive without getting side effects from it.

During the study, participants will receive one infusion of TAK-881 under the skin (subcutaneous infusion) on Day 1 at a lower dose level followed by participants receiving one infusion of higher dose levels with ongoing safety monitored by the doctor to ensure optimal tolerability and safety.

Participants will stay in the clinic for 4 days and will come back after 4 weeks. A follow up visit will take place 12 weeks after the TAK-881 infusion.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An understanding, ability, and willingness to fully comply with study procedures and restrictions.
  • Ability to voluntarily provide written, signed, and dated (personally or via a legally-authorized representative) as applicable to participate in the study.
  • Age 19-50 years inclusive at the time of consent. The date of signature of the informed consent is defined as the beginning of the screening period. This inclusion criterion will only be assessed at the first screening visit.
  • Male, or non-pregnant, non-breastfeeding female who agrees to comply with any applicable requirements of the protocol, or female of non-.
  • Must be considered "healthy." Healthy as determined by the investigator on the basis of screening evaluations. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead (ECG), hematology, blood chemistry, and urinalysis.
  • (BMI) between 18.0 and 30.0 kilogram per square meter (kg/m\^2) inclusive.

Exclusion criteria

Exclusion Criteria:

  • Any current or relevant history of medical (e.g., any hematological, hepatic, respiratory, cardiovascular, renal, or neurological) or psychiatric conditions, which by judgment of the investigator might compromise the safety of the participant or integrity of the study, interfere with the participants participation in the trial and compromise the trial objectives, or any condition that presents an undue risk from the IP or procedures.

Note: Participants on stable dose of hormone replacements (e.g., thyroid hormone replacement) or oral are permitted.

  • cardiac conditions including but not limited to uncontrolled hypertension, myocardial infarction, unstable coronary artery disease and clinically significant arrhythmias and conduction disorders.
  • Known or suspected intolerance or to the IP(s), closely related compounds, or any of the stated ingredients (e.g., human immune globulin (IG), hyaluronidase, albumin).
  • Known history of hypersensitivity or severe allergic reactions (e.g., urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following administration of blood or blood components.
  • Known allergy to hyaluronidase of human (including recombinant human hyaluronidase) or animal origin (such as bee or wasp venom).
  • Significant illness, as judged by the investigator, within 30 days of the first dose of IP.
  • Known history of alcohol or other substance abuse within the last year.
  • Donation of blood within 60 days, or blood products (e.g., plasma or ) within 2 weeks prior receiving the first dose of IP.
  • Participants will be excluded if abnormal hematology, chemistry, and other laboratory values are greater than (>)10% above the (ULN) or >10% below the lower limit of normal (LLN) except for liver function tests and absolute neutrophils. Participants will be excluded if any of the following laboratory parameters meet the criteria below:

    • less than (\<) 1.5* 10\^9 cells/liter
    • Liver function: (ALT) greater than or equal to (>=) 1.5* ULN, aspartate aminotransferase (AST) >=1.5* ULN, alkaline phosphatase (ALP) >=1.5* ULN, or total >=1.5 milligram per deciliter (mg/dL)
  • Participants will be excluded if any other laboratory values are outside the reference range and are clinically significant per investigator's judgment.
  • Participants who, within 30 days prior to the first dose of IP:

    • Have participated in another clinical study involving IG products within 12 months of screening.
    • Have used an IP (or 5 half-lives, whichever is longer).
    • Have been enrolled in a clinical study (including vaccine studies or has been vaccinated with approved product) that, in the investigator's opinion, may impact this study. Participants who have received any vaccine (including and COVID-19 vaccines) during the last 30 days before dosing will be excluded. No live attenuated virus vaccines are allowed during the study until the end of the follow-up period.
    • Have had any substantial changes in eating habits, as assessed by the investigator.
  • Confirmed systolic blood pressure >139 millimeter of mercury (mmHg) or \<89 mmHg and diastolic blood pressure >89 mmHg or \<49 mmHg.
  • A positive screen for alcohol or drugs of abuse at screening or Day -1 (D-1).
  • A positive (HIV), virus (HCV), or ongoing/active infection at screening. Participants with immunity to hepatitis B from either active vaccination or from previous natural infection are eligible to participate in the study.
  • Smoking more than 5 cigarettes or equivalent per day, unable to stop smoking during confinement in the clinical research center (CRC).
  • Severe dermatitis or anatomical abnormality that would interfere with TAK-881 administration or endpoint assessments. Note: The skin at the administration site should not be covered by tattoos.
  • Current use of any herbal or homeopathic preparations is not permitted.
  • Unable or unwilling to discontinue antihistamines or medications with antihistamine properties, sedatives, anxiolytics, systemic , or topical steroids or antibiotics on any area below the chest for a minimum of 48 hours prior to infusion visit and through 72 hours post infusion.
  • Current or relevant history of hypercoagulable conditions (e.g., Protein C, Protein S, and antithrombin III deficiency), thrombotic/thromboembolic events or venous thrombosis.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    TAK-881 0.4 g/kg (in-line warmed)

    Participants will receive a single dose of TAK-881 comprising of 0.4 gram per kilogram (g/kg) (in-line warmed) Immune Globulin Subcutaneous (IGSC), 20 percent (%) at progressively increased infusion rates and Recombinant Human Hyaluronidase (rHuPH20) dose of 80 unit per gram (U/g) immunoglobulin G (IgG) on Day 1 of the study treatment period.

    Biological: TAK-881

  • Experimental
    TAK-881 1.0 g/kg (in-line warmed)

    Participants will receive a single dose of TAK-881 comprising of 1.0 g/kg (in-line warmed) IGSC, 20% at progressively increased infusion rates and rHuPH20 dose of 80 U/g IgG on Day 1 of the study treatment period.

    Biological: TAK-881

  • Experimental
    TAK-881 1.0 g/kg (un-warmed)

    Participants will receive a single dose of TAK-881 comprising of 1.0 g/kg (un-warmed) IGSC, 20% at progressively increased infusion rates and rHuPH20 dose of 80 U/g IgG on Day 1 of the study treatment period.

    Biological: TAK-881

Interventions

  • BiologicalTAK-881

    Participants will receive subcutaneous infusion of TAK-881 on Day 1.

    Also known as: Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Tolerability Events Related to Infusion of TAK-881 Per Infusion Site

    A tolerability event was considered to have occurred if an infusion was tolerable. An infusion was considered tolerable if the infusion rate was not reduced or the infusion was not interrupted or stopped, due to any treatment-emergent adverse event (TEAE) related to TAK-881. Number of participants with tolerability events related to infusion of TAK-881 per infusion sites (1 and 2) were reported.

    Time frame: Up to Day 4

Secondary outcomes

  1. Number of Participants With TEAEs

    A TEAE was defined as any event emerged or manifested at or after the initiation of treatment with an Investigational product (IP) or medicinal product or any existing event that worsened in either intensity or frequency following exposure to the IP or medicinal product. Any clinically significant treatment-emergent changes in clinical laboratory measurements and vital signs were recorded as TEAEs. Number of participants with TEAEs were reported.

    Time frame: From the start of study drug administration up to Week 13

  2. Number of Participants With Positive Binding Anti-Drug Antibodies (ADA) and Neutralizing Antibodies to rHuPH20

    Positive binding ADA was defined as titer greater than or equal to (\>=) 1:160. Neutralizing antibodies were only tested if binding ADA titer was \>= 1:160. Number of participants with positive binding ADA and neutralizing antibodies to rHuPH20 were reported.

    Time frame: Baseline up to Week 13

  3. Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site

    The maximum tolerable infusion rate achieved referred to the administration of IGSC, 20% at progressively increasing infusion rates and was defined as the highest infusion rate achieved at which the infusion was tolerable (i.e., no stopping, interruption, or infusion rate reduction due to a TAK-881-related TEAE). The maximum tolerable infusion rate for Infusion Site 2 depended on the planned volume according to the stepwise infusion rate escalation regimen. Number of participants who achieved maximum tolerable infusion rate per infusion sites (1 and 2) for each infusion rate (30, 60, 120, 180, and 300 milliliter per hour \[mL/hour\]) were reported.

    Time frame: Day 1 up to Day 4

  4. Total Volume Infused Per Infusion Site for rHuPH20 and IGSC

    Total volume infused per infusion sites (1 and 2) for rHuPH20 and IGSC were reported.

    Time frame: At Day 1

  5. Time to Deliver the Total Infused Volume Per Infusion Site

    Time to deliver (in minutes) the total infused volume was calculated as (stop date/time of IGSC 20% administration) - (start date/time of rHuPH20 administration). Time to deliver the total infused volume per infusion sites (1 and 2) were reported.

    Time frame: At Day 1

07

Results

Posted Jan 12, 2024

Participant flow

This study was conducted at single center in the United States from 12 October 2021 to 12 April 2022.

Participant flow — Overall Study
MilestoneTAK-881 0.4 g/kg WarmedTAK-881 1.0 g/kg WarmedTAK-881 1.0 g/kg Un-warmed
Started888
Completed887
Not completed001
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryNumber of Participants With Tolerability Events Related to Infusion of TAK-881 Per Infusion Site

A tolerability event was considered to have occurred if an infusion was tolerable. An infusion was considered tolerable if the infusion rate was not reduced or the infusion was not interrupted or stopped, due to any treatment-emergent adverse event (TEAE) related to TAK-881. Number of participants with tolerability events related to infusion of TAK-881 per infusion sites (1 and 2) were reported.

Time frame:
Up to Day 4
Reported as:
Count of participants · Participants
Number of Participants With Tolerability Events Related to Infusion of TAK-881 Per Infusion Site
ParticipantsTAK-881 0.4 g/kg WarmedTAK-881 1.0 g/kg WarmedTAK-881 1.0 g/kg Un-warmed
Infusion Site 1888
Infusion Site 2—47
SecondaryNumber of Participants With TEAEs

A TEAE was defined as any event emerged or manifested at or after the initiation of treatment with an Investigational product (IP) or medicinal product or any existing event that worsened in either intensity or frequency following exposure to the IP or medicinal product. Any clinically significant treatment-emergent changes in clinical laboratory measurements and vital signs were recorded as TEAEs. Number of participants with TEAEs were reported.

Time frame:
From the start of study drug administration up to Week 13
Reported as:
Count of participants · Participants
Number of Participants With TEAEs
ParticipantsTAK-881 0.4 g/kg WarmedTAK-881 1.0 g/kg WarmedTAK-881 1.0 g/kg Un-warmed
Number of Participants With TEAEs888
SecondaryNumber of Participants With Positive Binding Anti-Drug Antibodies (ADA) and Neutralizing Antibodies to rHuPH20

Positive binding ADA was defined as titer greater than or equal to (\>=) 1:160. Neutralizing antibodies were only tested if binding ADA titer was \>= 1:160. Number of participants with positive binding ADA and neutralizing antibodies to rHuPH20 were reported.

Time frame:
Baseline up to Week 13
Reported as:
Count of participants · Participants
Number of Participants With Positive Binding Anti-Drug Antibodies (ADA) and Neutralizing Antibodies to rHuPH20
ParticipantsTAK-881 0.4 g/kg WarmedTAK-881 1.0 g/kg WarmedTAK-881 1.0 g/kg Un-warmed
Binding Antibodies000
SecondaryNumber of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site

The maximum tolerable infusion rate achieved referred to the administration of IGSC, 20% at progressively increasing infusion rates and was defined as the highest infusion rate achieved at which the infusion was tolerable (i.e., no stopping, interruption, or infusion rate reduction due to a TAK-881-related TEAE). The maximum tolerable infusion rate for Infusion Site 2 depended on the planned volume according to the stepwise infusion rate escalation regimen. Number of participants who achieved maximum tolerable infusion rate per infusion sites (1 and 2) for each infusion rate (30, 60, 120, 180, and 300 milliliter per hour \[mL/hour\]) were reported.

Time frame:
Day 1 up to Day 4
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site
ParticipantsTAK-881 0.4 g/kg WarmedTAK-881 1.0 g/kg WarmedTAK-881 1.0 g/kg Un-warmed
Infusion Site 1: 30 mL/hour000
Infusion Site 1: 60 mL/hour000
Infusion Site 1: 120 mL/hour000
Infusion Site 1: 180 mL/hour000
Infusion Site 1: 300 mL/hour888
Infusion Site 2: 30 mL/hour—00
Infusion Site 2: 60 mL/hour—02
Infusion Site 2: 120 mL/hour—01
Infusion Site 2: 180 mL/hour—11
Infusion Site 2: 300 mL/hour—33
SecondaryTotal Volume Infused Per Infusion Site for rHuPH20 and IGSC

Total volume infused per infusion sites (1 and 2) for rHuPH20 and IGSC were reported.

Time frame:
At Day 1
Reported as:
Mean · milliliter (mL)
Total Volume Infused Per Infusion Site for rHuPH20 and IGSC
milliliter (mL)TAK-881 0.4 g/kg WarmedTAK-881 1.0 g/kg WarmedTAK-881 1.0 g/kg Un-warmed
rHuPH20: Infusion Site 114.3 ± 1.2829.3 ± 1.3929.4 ± 1.77
rHuPH20: Infusion Site 2—10.0 ± 5.167.3 ± 6.16
IGSC 20%: Infusion Site 1141.3 ± 13.30291.3 ± 14.33293.8 ± 17.68
IGSC 20%: Infusion Site 2—97.5 ± 51.7270.0 ± 61.64
SecondaryTime to Deliver the Total Infused Volume Per Infusion Site

Time to deliver (in minutes) the total infused volume was calculated as (stop date/time of IGSC 20% administration) - (start date/time of rHuPH20 administration). Time to deliver the total infused volume per infusion sites (1 and 2) were reported.

Time frame:
At Day 1
Reported as:
Median · minute
Time to Deliver the Total Infused Volume Per Infusion Site
minuteTAK-881 0.4 g/kg WarmedTAK-881 1.0 g/kg WarmedTAK-881 1.0 g/kg Un-warmed
Infusion Site 163.5 (59 to 74)99.5 (92 to 103)102.0 (91 to 112)
Infusion Site 2—53.0 (35 to 68)41.0 (22 to 69)

Adverse events

Collected over From the start of study drug administration up to Week 13. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TAK-881 0.4 g/kg Warmed0/8 (0%)0/8 (0%)8/8 (100%)
TAK-881 1.0 g/kg Warmed0/8 (0%)0/8 (0%)8/8 (100%)
TAK-881 1.0 g/kg Un-warmed0/8 (0%)0/8 (0%)8/8 (100%)
Most frequent other events
Most frequent other events
EventTAK-881 0.4 g/kg WarmedTAK-881 1.0 g/kg WarmedTAK-881 1.0 g/kg Un-warmed
Infusion site erythemaGeneral disorders8/88/88/8
Infusion site swellingGeneral disorders7/88/88/8
Infusion site painGeneral disorders4/85/84/8
Infusion site pruritusGeneral disorders3/85/85/8
DiarrhoeaGastrointestinal disorders1/80/80/8
DizzinessNervous system disorders0/80/81/8
HeadacheNervous system disorders1/80/81/8
Infusion site extravasationGeneral disorders1/80/80/8
NauseaGastrointestinal disorders1/80/80/8

Baseline characteristics

Safety set included all participants who received a partial or a full dose of TAK-881.

Age, Continuous
Age, Continuous(years)TAK-881 0.4 g/kg WarmedTAK-881 1.0 g/kg WarmedTAK-881 1.0 g/kg Un-warmedTotal
Mean42.6 ± 4.5739.4 ± 4.1034.9 ± 10.1239.0 ± 7.29
Sex: Female, Male
Sex: Female, Male(Participants)TAK-881 0.4 g/kg WarmedTAK-881 1.0 g/kg WarmedTAK-881 1.0 g/kg Un-warmedTotal
Female52411
Male36413
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TAK-881 0.4 g/kg WarmedTAK-881 1.0 g/kg WarmedTAK-881 1.0 g/kg Un-warmedTotal
Hispanic or Latino87823
Not Hispanic or Latino0101
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TAK-881 0.4 g/kg WarmedTAK-881 1.0 g/kg WarmedTAK-881 1.0 g/kg Un-warmedTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0101
White87823
More than one race0000
Unknown or Not Reported0000
08

Study locations

1 site
  • Clinical Pharmacology of Miami
    Hialeah, Florida 33014, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Apr 2022, 6 months.

Results were first posted in Jan 2024, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2021
First posted
Sep 28, 2021
StartActual
Oct 12, 2021
Primary completionActual
Apr 12, 2022
CompletionActual
Apr 12, 2022
Results first posted
Jan 12, 2024
Last update
Jan 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05059977
Lead sponsor
Takeda
Collaborators
Takeda Development Center Americas, Inc., Baxalta Innovations GmbH, now part of Shire
Responsible party
Sponsor
First posted
Sep 28, 2021
Start date
Oct 12, 2021
Primary completion
Apr 12, 2022
Completion
Apr 12, 2022
Results posted
Jan 12, 2024
Last update
Jan 12, 2024

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion